Statins in the prevention of cardiovascular events in patients with renal failure

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 7, Issue 1, 2007, Pages 7-13

  Buemi, Michele ^a   Floccari, Fulvio ^a   Nostro, Lorena ^a   Campo, Susanna ^a   Caccamo, Chiara ^a   Sturiale, Alessio ^a   Aloisi, Carmela ^a   Giacobbe, Maria Stella ^a   Frisina, Nicola ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Cardiovascular disease (CVD); Dialysis; HMG coenzyme A reductase inhibitors; Nephropathic patients; Transplantation

Indexed keywords

ANTIBIOTIC AGENT; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; COMPACTIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG HALF LIFE; DRUG WITHDRAWAL; EPIDEMIOLOGICAL DATA; HEART ATRIUM FIBRILLATION; HEART DILATATION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HEMODIALYSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER; META ANALYSIS; MUSCLE; MUSCLE DISEASE; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SYSTEMATIC REVIEW;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; RENAL DIALYSIS;

EID: 33947185668     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Shlipak, M.G.; Fried, L.F.; Cushman, M.; Manollo, T.A.; Peterson, D.; Stehman-Breen, C.; Bleyer, A.; Newman, A.; Siscovick, D.; Psathy, B. Cardiovascular mortality risk in chronic kidney disease comparison of traditional and novel risk factors. JAMA, 2005, 293, 1737-1745.
2. Damsgaard, E.M.; Froland, A.; Jorgensen, O.D.; Mogensen, C.E. Microalbuminuria as predictor of increased mortality in elderly people. BMJ, 1990, 300, 297-300.
3. Wannamethee, S.G.; Shaper, A.G.; Perry, I.J. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. Stroke, 1997, 28, 557-63.
4. Culleton, B.F.; Larson, M.G.; Wilson, P.W.; Evans, J.C.; Parfrey, P.S.; Levy, D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int., 1999, 56, 2214-9.
5. Ruilope, L.M.; Salvetti, A.; Jamerson, K.; Hansson, L.; Warnold, I.; Wedel, H.; Zanchetti, A. Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) Study. J. Am. Soc. Nephrol., 2001, 12, 218-25.
6. Mann, J.F.; Gerstein, H.C.; Pogue, J.; Bosch, J.; Yusuf, S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann. Intern. Med., 2001, 134, 629-36.
7. Langford, H.G.; Stamler, J.; Wassertheil-Smoller, S.; Prineas, R.J. All-cause mortality in the Hypertension Detection and Follow-up Program: findings for the whole cohort and for persons with less severe hypertension, with and without other traits related to risk of mortality. Prog. Cardiovasc. Dis., 1986, 29(Suppl. 1), 29-54.
8. Drey, N.; Roderick, P.; Mullee, M.; Rogerson, M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am. J. Kidney. Dis., 2003, 42, 677-84.
9. Shlipak, M.G.; Simon, J.A.; Grady, D.; Lin, F.; Wenger, N.K.; Furberg, C.D. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J. Am. Coll Cardiol., 2001, 38, 705-11.
10. Shlipak, M.G.; Heidenreich, P.A.; Noguchi, H.; Chertow, G.M.; Browner, W. S.; McClellan, M.B. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann. Intern. Med., 2002, 137, 555-62.
11. Muntner, P.; He, J.; Hamm, L.; Loria, C.; Whelton, P.K. Renal insufficiency and subse quent death resulting from cardiovascular disease in the United States. J. Am. Soc. Nephrol., 2002, 13, 745-53.
12. Go, A.S.; Chertow, G.M.; Fan, D.; McCulloch, C.E.; Hsu, C. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. New. Engl. J. Med., 2004, 351, 213:1296-1304.
13. Meyer, K.B.; Levey, A.S. Controlling the epidemic of cardiovascular disease in chronic renal disease: report from the National Kidney Foundation Task Force on cardiovascular disease. J. Am. Soc. Nephrol., 1998, 9, S31-S42.
14. U.S. Renal Data System. Excerpts from United States Renal Data System 2001 Annual Data Report. Am. J. Kidney. Dis., 2001, 38, S147-S158.
15. O'Hare, A.M.; Hsu, C.Y.; Bacchetti, P.; Johansen, K.L. Peripheral vascular disease risk factors among patients undergoing hemodialysis. J. Am. Soc. Nephrol., 2002, 13, 497-503.
16. Garg, A.X.; Clark, W.F.; Haynes, B.; House, A.A. Moderate renal insufficiency and the risk of cardiovascular mortality: results from NHANES I. Kidney Int., 2002, 61, 1486-1494.
17. Lindner, A.; Charra, B.; Sherrard, D.J.; Scribner, B.H. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N. Engl. J. Med., 1974, 290(13), 697-701
18. Steinberg, D.; Gotto, A.M. Preventing coronary artery disease by lowering cholesterol levels. Fifty years from bench to bedside. JAMA, 1999, 282, 2043-2050.
19. Guijarro, C.; Keane, W.F. Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis. Miner Electrolyte Metab., 1996, 22, 147-152.
20. Buemi, M.; Allegra, A.; Corica, F.; Aloisi, C.; Giacobbe, M.S.; Pettinato, G.; Corsonello, A.; Senatore, M.; Frisina, N. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin. Pharmacol. Ther., 2000, 67 (4), 427-31.
21. Buemi, M.; Senatore, M.; Corica, F.; Aloisi, C.; Romeo, A.; Cavallaro, E.;Floccari, F.; Tramontana, D.; Frisina, N. Statins and progressive renal disease. Med. Res. Rev., 2002, 22, 76-84.
22. Buemi, M.; Senatore, M.;Corica, F.; Aloisi, C.; Romeo, A.; Cavallaro, E.; Frisina, N. Are there potential non-lipid-lowering uses of statins in the kidney? Nephron, 2001, 89(4), 363-8.
23. Marchiali, R.; Marfisi, R.M. Prevenzione primaria e secondaria della cardiopatia ischemica. Dalla metanalisi e dalla metaregressione ai meccanismi biologici: riflessioni per una pratica clinica basata sull'evidenza scientifica. G. Ital. Cardiol., 1998, 28, 434-459
24. Buemi, M.; Senatore, M.; Corica, F.; Aloisi, C.; Romeo, A.; Cavallaro, E.; Floccari, F.; Nostro, L.; Frisina, N. Statins multiple faces: a not only hypocholesterolemizing cardionephrological therapy in Cardionephrology 7 Bios Editoriale 417-424-2002 Assisi.
25. Buemi, M.; Aloisi, C.; Floccari, F.; Caccamo, C.; Cavallaro, E.; Crascì, E.; Criseo, M.; Corica, F.; Frisina, N. Cardiorenal consequences of atherosclerosis and statins therapy: from the past to the future. Curr Pharm Design (in press).
26. Schachter, M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol., 2004, 19, 117-125.
27. Shepherd, J.; Cobbe, S.M.; Ford, I. (for the West of Scotland coronary prevention study group) prevention of coronary heart disease with pravastatin in men and hypercholesterolemia. N. Engl. J. Med., 1995, 333, 1301-1307.
28. Downs, J.R.; Clearfield, M.; Weis, S. (for the air force/texas coronary atherosclerosis prevention study group: primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA, 1998, 279, 1616-1622.
29. Pitt, B.; Mancini, G.B.J.; Ellis, S.G.; Rosman, H.S.; Park, J.S.; McGovern, M.E (for the PLAC I investigators): Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I) reduction in atherosclerosis progression and clinical events. J. Am. Coll. Cardiol., 1995, 26, 1133-1139.
30. Cheung, B.M.; Lauder, I.J.; Lau, C.P.; Kumana, C.R. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br. J. Clin. Pharmacol., 2004, 57(5), 640-51.14.
31. Tveit, A.; Grundtvig, M.;Gundersen, T.; Vanberg, P.;Semb, A.G.; Holt, E.; Gullestad, L. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am. J. Cardiol., 2004, 93, 780-782.
32. Chiu, J.H.; Abdelhadi, R.H.; Chung, M.K.; Gurm, H.S.; Marrouche, N.F.; Saliba, W.I.; Natale, A.; Martin, D.O. Effect of statin therapy on risk ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. Am. J. Cardiol., 2005, 95, 490-491.
33. Heeschen, C.; Hamm, C.W.; Laufs, U.; Snapinn, S.; Bohm, M.; White, H.D. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation, 2002, 105(12), 1446-52.
34. Scandinavian simvastatin survival study group: randomized trial of cholesterol lowering in 4, 444 patients with coronary artery disease: The Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344, 1383-1389.
35. Saks, F.M.; Pfeffer, M.A.; Moye, L.A The effect of pravastatin on coronary events after myocardial infarction in patients with awerage cholesterol levels. N. Engl. J. Med., 1996, 335, 1001-1009.
36. Senatore, M.; Buemi, M. HMG-CoA reductase inhibitors and apoptosis. Nephron, 1999, 81(4), 439-40.
37. Alaupovic, P.; Fesmire, J.D.; Hunnighake, D.; Domanski, M.; Forman, S.; Knatterud, G.L.; Forrester, J.; Herd, J.A.; Hoogwerf, B.; Campeau, L.; Gobel, F.L. Post coronary artery bypass graft trial investigator: the effects of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. Atherosclerosis, 1999, 146(2), 369-79
38. The long-term intervention of pravastatin in ischemic disease (LIPID) Study group: prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med., 1998, 339, 1349-1357.
39. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. N. Engl. J. Med., 1998, 339, 1349-1357.
40. Tonelli, M.; Isles, C.; Curhan, G.C.; Tonkin, A.; Pfeffer, M.A.; Shepherd, J.; Sacks, F.M.; Furberg, C.; Cobbe, S.M.; Simes, J.; Craven, T.; West, M. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation, 2004, 110(12), 1557-63.
41. Colhoun, H.M.; Betteridge, D.J.; Durrington, P.N.; Hitman, G.A.; Neil, H.A.; Livingstone, S.J.; Thomason, M.J.; Mackness, M.I.; Charlton-Menys, V.; Fuller, J.H. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004, 364(9435), 685-96
42. Liu, Y.; Coresh, J.; Eustace, J.A.; Longenecker, J.C.; Jaar, B.; Fink, N.E.; Tracy, R.P.; Powe, N.R.; Klag, M.J. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA, 2004, 291(4), 451-9
43. Seliger, S.L.; Weiss, N.S.; Gillen, D.L.; Kestenbaum, B.; Ball, A.; Sherrard, D.J.; Stehman-Breen, C.O. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int., 2002, 61(1), 297-304.
44. Mason, N.A.; Bailie, G.R.; Satayathum, S.; Bragg-Gresham, J.L.; Akiba, T.; Akizawa, T.; Combe, C.; Rayner, H.C.; Saito, A.; Gillespie, B.W.; Young, E.W. HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am. J. Kidney Dis., 2005, 45(1), 119-26.
45. Wang, A.Y.; Ho, S.S.; Wang, M.; Liu, E.K.; Ho, S.; Li, P.K.; Lui, S.F.; Sanderson, J.E. Cardiac valvular calcification as a marker of atherosclerosis and arterial calcification in end-stage renal disease. Arch. Intern. Med., 2005, 165(3), 327-32.
46. Wu, B.; Elmariah, S.; Kaplan, F.S.; Cheng, G.; Mohler, E.R 3rd. Paradoxical effects of statins on aortic valve myofibroblasts and osteoblasts: implications for end-stage valvular heart disease. Arterioscler. Thromb. Vasc. Biol., 2005, 25(3), 592-7.
47. Cosio, F.G.; Pesavento, T.E.; Pelletier, R.P.; Henry, M.; Ferguson, R.M.; Kim, S.; Lemeshow S. Patient survival after renal transplantation III: the effects of statins. Am. J. Kidney Dis., 2002, 40(3), 638-43.
48. Holdaas, H.; Fellstrom, B.; Jardine, A.G.; Holme, I.; Nyberg, G.; Fauchald, P.; Gronhagen-Riska, C.; Madsen, S.; Neumayer, H.H.; Cole, E.; Maes, B.; Ambuhl, P.; Olsson, A.G.; Hartmann, A.; Solbu, D.O.; Pedersen, T.R. Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet, 2003, 361(9374), 2024-31.
49. Holdaas, H.; Fellstrom, B.; Jardine, A.G. on behalf of the ALERT study group. Clinical Practice Guidelines for Managing Dyslipidemias in Kidney Transplant Patients: Lessons to be Learnt From the Assessment of Lescol in Renal Transplantation (ALERT) Trial. Am. J. Transplant, 2005, 5(6), 1574-5.
50. Baigent, C.; Landray, M.; Leaper, C.; Altmann, P.; Armitage, J.; Baxter, A.; Cairns, H.S.; Collins, R.; Foley, R.N.; Frighi, V.; Kourellias, K.; Ratcliffe, P.J.; Rogerson, M.; Scoble, J.E.; Tomson, C.R.; Warwick, G.; Wheeler, D.C. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am. J. Kidney Dis., 2005, 45(3), 473-84
51. Krane, V.; Wanner, C. Statins and aspirin in chronic kidney disease: what does the UK-HARP-I trial tell us? Am. J. Kidney Dis., 2005, 45(3), 607-9.